HMGB1 as a potential new marker of disease activity in patients with multiple sclerosis

被引：0
作者：
Maria Bucova
Beata Majernikova
Vladimira Durmanova
Daniela Cudrakova
Karin Gmitterova
Iveta Lisa
Eleonora Klimova
Kristina Kluckova
Milan Buc
机构：
[1] Comenius University,Institute of Immunology, Faculty of Medicine
[2] Comenius University and University Hospital,1st. Department of Neurology, Faculty of Medicine
[3] Comenius University,2nd Department of Neurology, Faculty of Medicine
[4] Faculty Hospital of JA Raiman,Centre for Therapy and Diagnosis of Multiple Sclerosis
来源：
Neurological Sciences | 2020年 / 41卷
关键词：
HMGB1; Immunity; Inflammation; Multiple sclerosis; EDSS; MSSS;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：599 / 604
页数：5
相关论文
共 50 条
  • [21] Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity
    Ingram, G.
    Bugert, J. J.
    Loveless, S.
    Robertson, N. P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (11) : 1386 - 1389
  • [22] RETINAL PERIPHLEBITIS IN MULTIPLE-SCLEROSIS - A MARKER OF DISEASE-ACTIVITY
    TOLA, MR
    GRANIERI, E
    CASETTA, I
    MONARI, P
    SCORRANO, R
    MAZZEO, V
    PAOLINO, E
    MONETTI, VC
    GOVONI, V
    EUROPEAN NEUROLOGY, 1993, 33 (02) : 93 - 96
  • [23] The potential roles of high mobility group box 1 (HMGB1) in musculoskeletal disease: A systematic review
    Gacaferi, Hamez
    Mimpen, Jolet Y.
    Baldwin, Mathew J.
    Snelling, Sarah J. B.
    Nelissen, Rob G. H. H.
    Carr, Andrew J.
    Dakin, Stephanie G.
    TRANSLATIONAL SPORTS MEDICINE, 2020, 3 (06) : 536 - 564
  • [24] The nuclear protein HMGB1, a new kind of chemokine?
    Degryse, B
    de Virgilio, M
    FEBS LETTERS, 2003, 553 (1-2) : 11 - 17
  • [25] Characteristics of cerebral blood flow in an Eastern sample of multiple sclerosis patients: A potential quantitative imaging marker associated with disease severity
    Zhou, Qinming
    Zhang, Tianxiao
    Meng, Huanyu
    Shen, Dingding
    Li, Yao
    He, Lu
    Gao, Yining
    Zhang, Yizongheng
    Huang, Xinyun
    Meng, Hongping
    Li, Biao
    Zhang, Min
    Chen, Sheng
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [26] HMGB1: A potential target for treatment of benign prostatic hyperplasia
    Xue Rui
    Ma Shengli
    Jia Zhankui
    Pi Guofu
    Yang Jinjian
    MEDICAL HYPOTHESES, 2013, 81 (05) : 892 - 895
  • [27] HMGB1 signals danger in acute coronary syndrome: Emergence of a new risk marker for cardiovascular death?
    Peter, Karlheinz
    Bobik, Alex
    ATHEROSCLEROSIS, 2012, 221 (02) : 317 - 318
  • [28] Smell as a Disease Marker in Multiple Sclerosis
    Printza, Athanasia
    Boziki, Marina
    Valsamidis, Constantinos
    Bakirtzis, Christos
    Constantinidis, Jannis
    Grigoriadis, Nikolaos
    Triaridis, Stefanos
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (17)
  • [29] Serum HMGB1 Serves as a Novel Laboratory Indicator Reflecting Disease Activity and Treatment Response in Ankylosing Spondylitis Patients
    Wang, Chenqiong
    Miao, Ye
    Wu, Xuefen
    Huang, Yishu
    Sun, Mengchen
    Zhu, Yingzi
    Zheng, Fang
    Sun, Wei
    Dong, Lingli
    JOURNAL OF IMMUNOLOGY RESEARCH, 2016, 2016
  • [30] A comparison of HMGB1 concentrations between cerebrospinal fluid and blood in patients with neurological disease
    Walker, Lauren Elizabeth
    Griffiths, Michael John
    McGill, Fiona
    Lewthwaite, Penelope
    Sills, Graeme John
    Jorgensen, Andrea
    Antoine, Daniel James
    Solomon, Tom
    Marson, Anthony Guy
    Pirmohamed, Munir
    BIOMARKERS, 2017, 22 (07) : 635 - 642
12345